Basic Medicine

Infectious Disease

Integration of Developmental Biology into Therapeutic Research on Viral Infections

Medical Sciences Course

  • Master / Doctoral Degree

Faculty

KODAMA, Eiichi NKODAMA, Eiichi N
KODAMA, Eiichi N

Professor, M.D. Ph.D.

  • TEL

    +81-22-717-8220

  • Mail

    skb96*irides.tohoku.ac.jp (Please convert "*" into "@".)

Research Theme

  • Development of antiviral agents
  • Mechanism of resistance
Research Keywords:

virus, rational drug design, resistance, mutation

Technical Keywords:

Drug development, Chemical biology, induction of resistance, biosafety

Laboratory Introduction

Viruses rapidly and effectively adapt to their given environment. Once viruses acquire infectivity to human, they show apparent and/or silent endemics like influenza viruses or human immunodeficiency viruses. For sufficient infection, they also have to fight with host immune system.
To overcome these suppressive factors for virus replication, evolution is a key role in virulence. Accumulation of numerous mutations enables viruses to fit with new host and to escape from immune system. It looks like a short history of biological evolution and diversity. Only the most adapted viruses can survive, while those without genetic changes nor adaptation will disappear.
In addition to the host immune system, we have developed robust weapons, antiviral agents. However, we understand that resistant viruses emerge under antiviral pressure. In our laboratory, we focus on aquisition of drug resistance and development of effective agents for these resistant variants, and pave the way for the novel viral therapeutics and pandemic/outbreak management.

Figure 1. Expected steric interactions between the 4’-ethynyl moiety of nucleoside reverse transcriptase (RT) inhibitor, EFdA-monophosphate Z. L. Salie <i>et al. PNAS</i> 2016;113:9274-9279

Figure 1. Expected steric interactions between the 4’-ethynyl moiety of nucleoside reverse transcriptase (RT) inhibitor, EFdA-monophosphate Z. L. Salie <i>et al. PNAS</i> 2016;113:9274-9279

Figure 2. HIV-1 infected MAGI cells stained with X-Gal are shown. F Miyamoto <i>et al. AVCC</i> 2015; 24:77-82

Figure 2. HIV-1 infected MAGI cells stained with X-Gal are shown. F Miyamoto <i>et al. AVCC</i> 2015; 24:77-82

Recent Publications

  • Salie Z. L. et al. Structuralbasis of HIV inhibition by translocation-defective RT inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA). Proc Natl Acad Sci U.S.A., 113:9274-9, 2016.
  • Watanabe M. et al. A novel peptide derived from the fusion protein heptad repeat inhibits replication of subacute sclerosing panencephalitis virus in vitro and in vivo. PLoS ONE 11: e0162823, 2016.
  • Asai T.et al. Use of a biosynthetic intermediate to explore the chemical diversity of pseudo-natural fungal polyketides. Nat Chem7: 737-43, 2015.
  • Hatanaka Y. et al. Histone chaperone CAF-1 mediates repressive histone modifications to protect preimplantation mouse embryos from endogenous retrotransposons. Proc Natl Acad Sci U.S.A., 112:14641-6, 2015.
  • Miyamoto F. et al. Anti-HIV-1 activity determined by β-galactosidase activity in the multinuclear activation of an indicator assay is comparable with that by a conventional focus counting method. Antiviral Chem Chemother 24:77-82, 2015.

Search for Laboratory

About